Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts

Diabetologia
Y TakedaM Monden

Abstract

Fas ligand (FasL) is highly expressed in testicular tissues and thought to be responsible for protection from allograft rejection by inducing apoptosis of anti-graft activated T cells. FasL-expressing islets have been shown to induce a granulocyte-mediated inflammatory reaction. We investigated whether a graft can be protected from alloimmune responses by manipulating the Fas/FasL-system. We transplanted allogeneic islets under the kidney capsule of streptozotocin-induced diabetic mice together with testicular tissue. Significant prolongation of survival of C3H islet allograft was observed in C57BL/6 (B6) recipients transplanted with C3H testicular tissue, but not in those transplanted with C3H-gld testicular tissue expressing non-functional FasL. No significant prolongation was observed in B6-lpr recipients expressing non-functional Fas. Immunohistochemical staining of C3H testicular tissue in the composite graft showed a high expression of FasL, but not that of the C3H-gld testicular tissue. In situ terminal deoxynucleotidyl transferase-mediated dUDP-biotin catalysed DNA nick-end labelling (TUNEL) staining of a composite graft of C3H islet and testicular tissue in B6 recipients demonstrated extensive apoptosis of infiltrating...Continue Reading

Citations

Jan 3, 2001·Transplantation Proceedings·M SchneiderF Richard
Dec 19, 1998·Molecular Medicine Today·A E WillingP R Sanberg
Nov 10, 2001·Annual Review of Biomedical Engineering·E L Chaikof
Dec 10, 2009·Reproduction : the Official Journal of the Society for the Study of Fertility·Payal MitalJannette M Dufour
Aug 12, 2004·Xenotransplantation·Lijun BaiBernard E Tuch
Nov 18, 2003·Immunological Reviews·A M James ShapiroJonathan R T Lakey
Nov 19, 2011·Immunotherapy·Ronald CharlesJohn J Fung
Nov 21, 2007·Advanced Drug Delivery Reviews·John T Wilson, Elliot L Chaikof
Aug 22, 2008·Cell Transplantation·Jannette M DufourRay V Rajotte
Feb 7, 2004·Cell Transplantation·Antonino Jara-AlbarránGranada Alvarez
Mar 17, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·S A WhiteM L Nicholson
Nov 13, 2004·Stem Cells·Osnat Bohana-Kashtan, Curt I Civin
Mar 27, 2019·Cell Proliferation·Sara ChiappalupiGuglielmo Sorci
May 26, 2001·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·F SebilleJ P Soulillou
Dec 19, 2019·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Kyle B WoodwardEsma S Yolcu
Dec 4, 2019·Journal of Drug Targeting·Mehwish Saba Aslam, Liudi Yuan
Feb 29, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·X SuY Wang
Oct 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Simonetta SipioneR Chris Bleackley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis